A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

计划入组 474 人 · 首次发布于 2023 年 9 月 25 日

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

计划入组 240 人 · 首次发布于 2024 年 11 月 12 日

SOURCE XT REGISTRY

计划入组 2,954 人 · 首次发布于 2010 年 11 月 10 日

XT-150

XT-044

XT-111

齐齐哈尔湃鳄生物科技有限公司

HAMILTON CDN BK MEAN RVSON IDX ETF UNIT

United States

CDC ENTEBBE

Uganda

Tempus Launches FDA-Approved xT CDx Test Nationwide for Comprehensive Solid Tumor Profiling

Tempus and Verastem Partner to Develop Companion Diagnostic for First FDA-Approved KRAS-Mutant LGSOC Treatment

Tempus AI Reports Strong Growth and Strategic Acquisition of Ambry Genetics in Q4 2024